North America Kirsten Rat Sarcoma (KRAS) Market, By Product (Reagents and Kits, Analyzers, Consumables), Cancer Type (Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Skin Cancer, Kidney Cancer, Blood Cancer, Ovarian Cancer, Others), Age Group (Adult, Pediatric), Application (Development of Molecular Diagnostics, Disease Diagnostics, Drug Discovery and Development, Personalised Medicine, Predictive, Research and Development, Therapeutic Approach/ Prognostics and Others), End User (Academic & Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Oncology Speciality Clinics, Pharma & Biotech Companies and Others), Distribution Channel (Direct Tenders, Retail Sales, Third Party Distributor) – Industry Trends and Forecast to 2030.
North America Kirsten Rat Sarcoma (KRAS) Market Analysis and Size
The rising interest in the antibodies will lead to the rise in Kirsten rat sarcoma (KRAS) research and is anticipated to boost the market's growth. Lung cancer is the second most common cancer, with around 2.0 million new lung cancer cases witnessed in 2018. The advancement in the field of biology caused the discovery of numerous oncogenes that play a major role in cancer development, therefore presenting researchers with opportunities to target them.
Data Bridge Market Research analyses a growth rate in the Kirsten rat sarcoma (KRAS) market in the forecast period 2023-2030. The expected CAGR of the Kirsten rat sarcoma (KRAS) market is around 4.50% in the mentioned forecast period. The market was valued at USD 91.41 million in 2022 and grow to USD 130 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Kirsten Rat Sarcoma (KRAS) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Reagents and Kits, Analyzers, Consumables), Cancer Type (Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Skin Cancer, Kidney Cancer, Blood Cancer, Ovarian Cancer, Others), Age Group (Adult, Pediatric), Application (Development of Molecular Diagnostics, Disease Diagnostics, Drug Discovery and Development, Personalised Medicine, Predictive, Research and Development, Therapeutic Approach/ Prognostics and Others), End User (Academic & Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Oncology Speciality Clinics, Pharma & Biotech Companies, and Others), Distribution Channel (Direct Tenders, Retail Sales, Third Party Distributor)
|
|
Countries Covered
|
U.S., Canada and Mexico
|
|
Market Players Covered
|
B.D. (U.S.), COSMED srl (Italy), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), Agilent Technologies Inc. (U.S.), Merck KGaA (Germany), Carestream Health (U.S.), • Illumina, Inc. (U.S.), Thermo Fisher Scientific (U.S.), AbbVie Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Kirsten rat sarcoma viral oncogene homolog (KRAS) is most frequently altered in RAS-mutated non small cell lung cancer cases. It belongs to a class of genes called oncogenes. It acts like a switch to activate downstream signaling pathways, which includes MAPK and PI3K that are involved in cell cycle regulation, metabolic changes, cell proliferation, cell survival and cell differentiation.
North America Kirsten Rat Sarcoma (KRAS) Market Dynamics
Drivers
- Increasing Research Activities
Researchers globally have known about KRAS mutations for many years, though the available therapies against it were proven to be indefinable. But after the approval of the first-ever KRAS inhibitor named Lumakras (Sotorasib) which was developed by Amgen in 2021 for the treatment of patients with advanced KRAS G12C mutated non-small cell lung cancer, the product market witnessed major growth in terms of both commercial sale success and improved overall survival rates. Its sales grew more than twice in 2022 than in 2021 levels. The drug is the first ever targeted anti-cancer treatment drug against KRAS mutations. Therefore, this factor increases the growth of the market.
Opportunities
- Increasing Rate of Product Launches
A growing number of product launches associated with vaccines are helpful in surging market growth. For instance, Qiagen also launched Therascreen KRAS RGQ PCR Kit after it received U.S. regulatory approval in helping the diagnosis of non-small cell lung cancer. This is the first companion diagnostic kit to have received premarket approval from the US FDA. However, the industry has made additional progress, and the FDA has further approved companion diagnosis kits. In 2022 Agilent Resolution's ctDx FIRST was approved by the FDA as a companion diagnostic for patients with NSCLC. Thus, this factor increases the market growth.
Restraints/Challenges
- Lack of Healthcare Professionals
Not every healthcare professional is very much known of this rare sarcoma; thus, it gets difficult to treat patients with this disease. This is a very complex disease its treatment process is also very complex. Thus, the lack of healthcare professionals leads to market hindrances.
This Kirsten rat sarcoma (KRAS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Kirsten rat sarcoma (KRAS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2020, Thermo Fisher Scientific Inc. announced to outspread of its collaboration with Symphogen to provide innovative cancer treatments via the optimization of protein characterization and quality monitoring mass spectrometry workflows. The companies can offer the biopharmaceutical industry compliance-ready mass spectrometer solutions to boost drug delivery.
North America Kirsten Rat Sarcoma (KRAS) Market Scope
The Kirsten rat sarcoma (KRAS) market is segmented on the basis of product, cancer type, age group, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Reagents and Kits,
- Analyzers,
- Consumables
Cancer Type
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer,
- Prostate Cancer
- Cervical Cancer
- Skin Cancer
- Kidney Cancer
- Blood Cancer
- Ovarian Cancer
- Others
Age Group
- Adult
- Pediatric
Application
- Development of Molecular Diagnostics
- Disease Diagnostics
- Drug Discovery and Development
- Personalised Medicine
- Predictive
- Research and Development
- Therapeutic Approach/ Prognostics
- Others
End User
- Academic & Cancer Research Institutes
- Diagnostic Laboratories
- Hospitals
- Oncology Speciality Clinics
- Pharma & Biotech Companies
- Others
Distribution Channel
- Direct Tenders
- Retail Sales
- Third Party Distributor
Kirsten Rat Sarcoma (KRAS) Market Regional Analysis/Insights
The Kirsten rat sarcoma (KRAS) market is analyzed and market size insights and trends are provided product, cancer type, age group, application, end user and distribution channel as referenced above.
The major countries covered in the Kirsten rat sarcoma (KRAS) market report are U.S., Canada and Mexico
U.S. is anticipated to grow with the highest CAGR in the forecast period due to the increasing incidence of cancer associated with Kristen rat sarcoma (KRAS) mutation and higher investment in R&D. The increasing frequency of Kristen rat sarcoma (KRAS) mutation and penetration of novel products boost the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Kirsten Rat Sarcoma (KRAS) Market Share Analysis
The Kirsten rat sarcoma (KRAS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Kirsten rat sarcoma (KRAS) market
Key players operating in the Kirsten rat sarcoma (KRAS) market include:
- B.D. (U.S.)
- COSMED srl (Italy)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- QIAGEN (Germany)
- Agilent Technologies Inc. (U.S.)
- Merck KGaA (Germany)
- Carestream Health (U.S.),
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific (U.S.
- AbbVie Inc. (U.S.)
SKU-